Eliaz Therapeutics Launches Reg CF Raise to Advance First Device Targeting Sepsis

Cover Image Eliaz Therapeutics Launches Reg CF Raise to Advance First Device Targeting Sepsis Santa Rosa, CA, USA, June 11, 2026 (GLOBE NEWSWIRE) -- FDA Breakthrough Device Designation Granted for XGal-3, an Investigational Apheresis Device Designed to Target Galectin-3 in Sepsis Patients Eliaz Therapeutics, Inc., a clinical-stage medical device company developing a first-of-its-kind apheresis device for the treatment of sepsis, has launched a new Regulation Crowdfunding (Reg CF) investment roun